All Photos(2)



ID8 Mouse Ovarian Surface Epithelial Cell Line

ID8 mouse ovarian surface epithelial cell line is frequently used as a syngeneic mouse model for human ovarian cancer.

Sign Into View Organizational & Contract Pricing

Select a Size


biological source



cell culture | mammalian: suitable

shipped in

liquid nitrogen

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item

cell culture | mammalian: suitable


cell culture | mammalian: suitable


cell culture | stem cell: suitable


cell culture | mammalian: suitable, cell differentiation: suitable

shipped in

liquid nitrogen

shipped in

dry ice

shipped in

liquid nitrogen

shipped in

liquid nitrogen

General description

ID8 is one of 10 clonal lines established from late passaged C57BL/6 murine ovarian surface epithelial cells (MOSEC) . Intraperitoneal injection of each of the 10 clonal lines into C57BL/6 mice resulted in formation of peritoneal tumors and ascitic fluid. Of the 10 clonal lines, ID8 exhibited the highest tumor load. ID8 cell line is a highly published and well characterized cell line and is frequently used as a syngeneic mouse model for ovarian cancer.
Ovarian cancer is the fourth leading cause of cancer-related deaths in women. The disease is frequently diagnosed at later stages, with tumors detected throughout the peritoneal cavity. Approximately 90% of ovarian tumors arise from ovarian surface epithelial cells . Human and mouse ovarian surface epithelial cells (OSE) have been isolated and are used to develop ovarian cancer models. These models typically involve injection of the human/mouse OSE cells subcutaneously, intraperitoneally or orthotopically into immune deficient mice. A common drawback to these models is the absence of an intact immune system in the host mice.

In 2000, an immune-competent syngeneic mouse model for ovarian cancer was reported . Mouse ovarian surface epithelial cells (MOSEC) isolated from C57BL/6 mice were found to spontaneously transform into malignant tumorigenic cells following prolonged passages in vitro . Late passage MOSEC lost the classical “cobblestone” contact-inhibited in vitro properties reminiscent of normal epithelial cells and instead grew as multi-layered cell clusters indicative of transformed cells. Intraperitoneal injection of late passaged MOSEC into athymic and normal, immune-intact, syngeneic C57BL/6 mice gave rise to tumors throughout the abdominal cavity like those observed in women with Stage III and IV cancer . MOSEC are thus useful syngeneic mouse models to study the role of the immune system in the establishment and progression of ovarian cancer.


• Each vial contains ≥ 1X106 viable cells.
• Cells are tested negative for infectious diseases by a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are verified to be of mouse origin and negative for inter-species contamination from rat, chinese hamster, Golden Syrian hamster, human and non-human primate (NHP) as assessed by a Contamination CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are negative for mycoplasma contamination

Other Notes

This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the "Academic Use Agreement" as detailed in the product documentation. For information regarding any other use, please contact

Storage Class Code

12 - Non Combustible Liquids



Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).


Product Number
Pack Size/Quantity

Additional examples:





enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Li Jiang et al.
Frontiers in immunology, 9, 2927-2927 (2019-01-09)
Fatty acid synthase (FASN), the key metabolic enzyme of de novo lipogenesis, provides proliferative and metastatic capacity directly to cancer cells have been described. However, the impact of aberrant activation of this lipogenic enzyme on host anti-tumor immune milieu remains
Zixiang Wang et al.
Nature communications, 13(1), 6246-6246 (2022-10-22)
Dysregulated expression of splicing factors has important roles in cancer development and progression. However, it remains a challenge to identify the cancer-specific splicing variants. Here we demonstrate that spliceosome component BUD31 is increased in ovarian cancer, and its higher expression
James Greenaway et al.
Gynecologic oncology, 108(2), 385-394 (2007-11-27)
Ovarian cancer is the fourth leading cause of cancer-related deaths among women and is among the least understood of all cancers. The objective of this study was to determine the effect of ovarian epithelial and stromal cell interaction in a
Qian-Feng Zhang et al.
Theranostics, 10(23), 10619-10633 (2020-09-16)
Great progress has been made in the field of tumor immunotherapy in the past decade. However, the therapeutic effects of immune checkpoint blockade (ICB) against ovarian cancer are still limited. Recently, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6i)
Michel Demeule et al.
Cancer science, 112(10), 4317-4334 (2021-07-28)
Triple-negative breast cancer (TNBC) is a heterogeneous subgroup of cancers which lacks the expression and/or amplification of targetable biomarkers (ie, estrogen receptor, progestrogen receptor, and human epidermal growth factor receptor 2), and is often associated with the worse disease-specific outcomes

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service